The grant will fund research on respiratory infections, the Antibiotic Use Optimization Program (PROA) incorporating a “One Health” perspective.
The cause is a change in the epigenetic pattern of the beta cells of the pancreas, which overexpress oncogenes and genes related to insulin production, thus altering their functioning.
A study describes how insulinomas, a rare type of pancreatic beta cell tumour, form Read More »
Neoadjuvant chemotherapy in breast cancer facilitates surgery and offers prognostic value. The 10-year survival rate is 84%, and 96% of patients who have a complete response to chemotherapy do not metastasize.
Researchers from IDIBELL and ICO have developed a bioinformatics algorithm that will improve the diagnosis of two cancer predisposition syndromes. This technique will speed up the diagnosis process and therapeutic decision-making in patients with suspected hereditary cancer.
This is the first time that this technology has been applied to asthma in Spain. Some months ago, this IDIBELL and HUB group launched a mobile app for the follow-up of this disease.
The study, led by Dr. Miguel Hueso, will help create alternatives to organ donation and dialysis for the treatment of chronic diseases, and the development of new drugs.
Researchers from Bellvitge University Hospital (HUB) and IDIBELL have participated in a clinical trial that has demonstrated the efficacy of sebetralstat, a new oral treatment for hereditary angioedema attacks.
Researchers have developed a genetic test that will improve the diagnosis of CMMRD, a rare cancer predisposition syndrome in children. The analysis of only a selection of genetic segments allows this test to be fast and accessible to healthcare professionals.
IDIBELL researchers have discovered a mechanism by which tumor cells respond differentially to various immunotherapies and have identified biomarkers that predict the response to these drugs. Published in Nature Communications, this finding would allow personalizing the treatment of skin carcinoma and thus increase the patients quality of life.
Researchers discover biomarkers that predict response to immunotherapy in skin carcinoma Read More »
At IDIBELL, we are proud to announce that this month the negotiating table for the first IDIBELL LGBTIAQ+ Plan has been constituted. Additionally, IDIBELL is inviting members to join the new Queer group, a meeting space for the LGBTIAQ+ community.
New Queer Group at IDIBELL to promote diversity in biomedical research Read More »
